Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Bowler

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
American Journal of Respiratory and Critical Care Medicine|December 3, 2021
Targeting the P2Y<sub>13</sub> Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental AsthmaRhiannon B Werder, Md Ashik Ullah, Muhammed Mahfuzur Rahman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.
Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.
Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.
American Journal of Respiratory and Critical Care Medicine|December 3, 2021
Targeting the P2Y<sub>13</sub> Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental AsthmaRhiannon B Werder, Md Ashik Ullah, Muhammed Mahfuzur Rahman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 5, 2021
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab RegistryDennis Thomas, Erin S Harvey, Vanessa M McDonald, et al.
Pageof 3